Martin Sanda

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint Health-related quality-of-life effects of watchful waiting re-evaluated in SPCG-4
    David W McDermott
    Prostate Center at Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Nat Clin Pract Urol 6:124-5. 2009
  2. doi request reprint A 64-year-old man with low-risk prostate cancer: review of prostate cancer treatment
    Martin G Sanda
    Harvard Medical School, Boston, Massachusetts, USA
    JAMA 301:2141-51. 2009
  3. pmc The role of the transcription factor SIM2 in prostate cancer
    Bin Lu
    Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 6:e28837. 2011
  4. doi request reprint Quality of life and satisfaction with outcome among prostate-cancer survivors
    Martin G Sanda
    Departments of Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Harvard University, Boston, MA 02215, USA
    N Engl J Med 358:1250-61. 2008
  5. ncbi request reprint Use of medications or devices for erectile dysfunction among long-term prostate cancer treatment survivors: potential influence of sexual motivation and/or indifference
    David C Miller
    Michigan Urology Center, University of Michigan Medical Center, Ann Arbor, Michigan, USA
    Urology 68:166-71. 2006
  6. ncbi request reprint Patterns of care for radical prostatectomy in the United States from 2003 to 2005
    Jim C Hu
    Division of Urologic Surgery, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Urol 180:1969-74. 2008
  7. ncbi request reprint Contemporary preoperative parameters predict cancer-free survival after radical prostatectomy: a tool to facilitate treatment decisions
    Caleb P Nelson
    Departments of Urology and Pathology, University of Michigan, Ann Arbor, MI, USA
    Urol Oncol 21:213-8. 2003
  8. ncbi request reprint Sexual health recovery after prostatectomy, external radiation, or brachytherapy for early stage prostate cancer
    Brent K Hollenbeck
    Division of Urology, Beth Israel Deaconess Medical Center, Rabb 440, 330 Brookline Avenue, Boston, MA 02215, USA
    Curr Urol Rep 5:212-9. 2004
  9. ncbi request reprint Obesity adversely affects health related quality of life before and after radical retropubic prostatectomy
    Jeffrey S Montgomery
    University of Michigan Urology Center, University Health System, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
    J Urol 176:257-61; discussion 261-2. 2006
  10. ncbi request reprint Determinants of long-term sexual health outcome after radical prostatectomy measured by a validated instrument
    Brent K Hollenbeck
    Department of Urology, University of Michigan, Ann Arbor, USA
    J Urol 169:1453-7. 2003

Detail Information

Publications52

  1. ncbi request reprint Health-related quality-of-life effects of watchful waiting re-evaluated in SPCG-4
    David W McDermott
    Prostate Center at Beth Israel Deaconess Medical Center, Boston, MA 02215, USA
    Nat Clin Pract Urol 6:124-5. 2009
    ....
  2. doi request reprint A 64-year-old man with low-risk prostate cancer: review of prostate cancer treatment
    Martin G Sanda
    Harvard Medical School, Boston, Massachusetts, USA
    JAMA 301:2141-51. 2009
    ....
  3. pmc The role of the transcription factor SIM2 in prostate cancer
    Bin Lu
    Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 6:e28837. 2011
    ..This study was designed to elucidate the role of SIM2 in prostate cancer using a shRNA-based approach in the PC3 prostate cancer cell line...
  4. doi request reprint Quality of life and satisfaction with outcome among prostate-cancer survivors
    Martin G Sanda
    Departments of Surgery, Beth Israel Deaconess Medical Center and Harvard Medical School, Harvard University, Boston, MA 02215, USA
    N Engl J Med 358:1250-61. 2008
    ....
  5. ncbi request reprint Use of medications or devices for erectile dysfunction among long-term prostate cancer treatment survivors: potential influence of sexual motivation and/or indifference
    David C Miller
    Michigan Urology Center, University of Michigan Medical Center, Ann Arbor, Michigan, USA
    Urology 68:166-71. 2006
    ..To evaluate the potential association between sexual motivation and patterns of erectile dysfunction (ED) therapy among a large cohort of localized prostate cancer treatment survivors...
  6. ncbi request reprint Patterns of care for radical prostatectomy in the United States from 2003 to 2005
    Jim C Hu
    Division of Urologic Surgery, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    J Urol 180:1969-74. 2008
    ..The demand for minimally invasive radical prostatectomy is increasing, although population based outcomes remain unclear. We assessed use and outcomes in American men undergoing radical prostatectomy...
  7. ncbi request reprint Contemporary preoperative parameters predict cancer-free survival after radical prostatectomy: a tool to facilitate treatment decisions
    Caleb P Nelson
    Departments of Urology and Pathology, University of Michigan, Ann Arbor, MI, USA
    Urol Oncol 21:213-8. 2003
    ..Tabulated 5-year PSA-free survival outcomes, stratified by these preoperative parameters, provide a basis for preoperative counseling of patients regarding postprostatectomy cancer control expectations...
  8. ncbi request reprint Sexual health recovery after prostatectomy, external radiation, or brachytherapy for early stage prostate cancer
    Brent K Hollenbeck
    Division of Urology, Beth Israel Deaconess Medical Center, Rabb 440, 330 Brookline Avenue, Boston, MA 02215, USA
    Curr Urol Rep 5:212-9. 2004
    ....
  9. ncbi request reprint Obesity adversely affects health related quality of life before and after radical retropubic prostatectomy
    Jeffrey S Montgomery
    University of Michigan Urology Center, University Health System, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA
    J Urol 176:257-61; discussion 261-2. 2006
    ..We used a validated health related quality of life measure to examine the effects of obesity on disease specific health related quality of life before and following radical retropubic prostatectomy...
  10. ncbi request reprint Determinants of long-term sexual health outcome after radical prostatectomy measured by a validated instrument
    Brent K Hollenbeck
    Department of Urology, University of Michigan, Ann Arbor, USA
    J Urol 169:1453-7. 2003
    ....
  11. ncbi request reprint Multiplex biomarker approach for determining risk of prostate-specific antigen-defined recurrence of prostate cancer
    Daniel R Rhodes
    Department of Pathology, University of Michigan School of Medicine, Ann Arbor, MI, USA
    J Natl Cancer Inst 95:661-8. 2003
    ....
  12. ncbi request reprint Long-term outcomes among localized prostate cancer survivors: health-related quality-of-life changes after radical prostatectomy, external radiation, and brachytherapy
    David C Miller
    Department of Urology, University of Michigan Medical Center, Ann Arbor, MI, USA
    J Clin Oncol 23:2772-80. 2005
    ..We sought to elucidate long-term changes in health-related quality-of-life (HRQOL) outcomes by prospectively re-evaluating a well-characterized cohort of prostate cancer (PC) survivors 4 to 8 years after primary treatment...
  13. ncbi request reprint Prognostic factors in lymph node-positive prostate cancer
    Matthias D Hofer
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Urology 67:1016-21. 2006
    ..The incidence of clinically localized PCa with concurrent lymph node metastasis has decreased to less than 1% in the United States but is between 10% and 15% in other countries...
  14. ncbi request reprint Preoperative parameters for predicting early prostate cancer recurrence after radical prostatectomy
    Caleb P Nelson
    Department of Urology, University of Michigan School of Medicine, Ann Arbor, Michigan, USA
    Urology 59:740-5; discussion 745-6. 2002
    ..Information relating preoperative parameters to recurrence-free survival is needed to counsel patients with newly diagnosed prostate cancer regarding expectations for postprostatectomy cancer control...
  15. ncbi request reprint Neoadjuvant hormonal therapy and older age are associated with adverse sexual health-related quality-of-life outcome after prostate brachytherapy
    Brent K Hollenbeck
    Department of Urology, University of Michigan Hospital, Ann Arbor, Michigan 48109 0330, USA
    Urology 59:480-4. 2002
    ..We used a validated HRQOL survey to characterize the significance of neoadjuvant hormonal therapy and other baseline factors on postimplantation sexual function and impairment...
  16. ncbi request reprint Long-term results of three-dimensional conformal adjuvant and salvage radiotherapy after radical prostatectomy
    Christina Tsien
    Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, Michigan 48109, USA
    Urology 62:93-8. 2003
    ..To evaluate the efficacy and toxicity of three-dimensional conformal radiotherapy (3D-CRT) in the adjuvant and salvage setting after radical prostatectomy (RP)...
  17. ncbi request reprint Measuring patients' expectations regarding health-related quality-of-life outcomes associated with prostate cancer surgery or radiotherapy
    Zvi Symon
    Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, Michigan, USA
    Urology 68:1224-9. 2006
    ..We prospectively studied the pretreatment expectations of prostate cancer-specific HRQOL with an adapted Expanded Prostate Cancer Index Composite instrument...
  18. pmc Measuring health-related quality of life consequences from primary treatment for early-stage prostate cancer
    Savita V Dandapani
    Harvard Medical School, Boston, MA, USA
    Semin Radiat Oncol 18:67-72. 2008
    ..This review will highlight prostate cancer HRQOL outcomes and delineate further areas of study necessary to optimize evidence-based decision making for prostate cancer patients...
  19. ncbi request reprint Patient, surgeon, and treatment characteristics associated with homologous blood transfusion requirement during radical retropubic prostatectomy: multivariate nomogram to assist patient counseling
    Atreya Dash
    Department of Urology, University of Michigan School of Medicine, Ann Arbor, Michigan, USA
    Urology 64:117-22. 2004
    ..Homologous blood transfusion is sometimes required during or after RRP, but predictive models for estimating transfusion probability using patient and surgical characteristics are lacking...
  20. pmc Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort
    William V Shappley
    Division of Urology, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA
    J Clin Oncol 27:4980-5. 2009
    ..To examine consequences of deferred treatment (DT) as initial management of prostate cancer (PCa) in a contemporary, prospective cohort of American men diagnosed with PCa...
  21. ncbi request reprint Postprostatectomy cancer-free survival of African Americans is similar to non-African Americans after adjustment for baseline cancer severity
    Willie Underwood
    Department of Urology, University of Michigan, Ann Arbor, MI, USA
    Urol Oncol 22:20-4. 2004
    ..Studies are needed to evaluate the possible interaction of prostate cancer stage and grade shift in African American men and the disease free survival in this population...
  22. ncbi request reprint Neoadjuvant hormonal therapy impairs sexual outcome among younger men who undergo external beam radiotherapy for localized prostate cancer
    Brent K Hollenbeck
    Department of Urology, University of Michigan School of Medicine, Ann Arbor, Michigan, USA
    Urology 63:946-50. 2004
    ..The effects of clinical and treatment factors on sexual health after external beam RT have not been fully characterized by patient-reported, validated questionnaires...
  23. ncbi request reprint Prostate cancer involving the bladder neck: recurrence-free survival and implications for AJCC staging modification. American Joint Committee on Cancer
    Atreya Dash
    Department of Urology, University of Michigan School of Medicine, Ann Arbor, Michigan 48109, USA
    Urology 60:276-80. 2002
    ..We therefore compared the recurrence risk in cases with bladder neck involvement with that of cases with extraprostatic extension and/or seminal vesicle invasion...
  24. ncbi request reprint Use of quality indicators to evaluate the care of patients with localized prostate carcinoma
    David C Miller
    Department of Urology, University of Michigan, Ann Arbor, Michigan 48109, USA
    Cancer 97:1428-35. 2003
    ..The objectives of this study were to evaluate the feasibility of measuring these quality indicators and to determine their sensitivity to change in practice patterns over time...
  25. ncbi request reprint The role of metastasis-associated protein 1 in prostate cancer progression
    Matthias D Hofer
    Department of Pathology, Brigham and Women s Hospital, Boston, Massachusetts, USA
    Cancer Res 64:825-9. 2004
    ..In summary, this study identified an association of MTA1 expression and prostate cancer progression...
  26. pmc Phase II trial of paclitaxel, carboplatin and gemcitabine in patients with locally advanced carcinoma of the bladder
    David C Smith
    Department of Internal Medicine, Division of Hematology Oncology, University of Michigan School of Medicine, University of Michigan, Ann Arbor, Michigan, USA
    J Urol 180:2384-8; discussion 2388. 2008
    ..This 2-arm phase II multicenter trial was designed to assess the efficacy and toxicity of neoadjuvant paclitaxel, gemcitabine and carboplatin in patients with invasive bladder cancer...
  27. doi request reprint Partially circumventing peripheral tolerance for oncogene-specific prostate cancer immunotherapy
    Yilin C Neeley
    Department of Urology, Surgery, and Pathology, University of Michigan Ann Arbor, Michigan, USA
    Prostate 68:715-27. 2008
    ..Failure of cancer immunotherapy is essentially due to immunological tolerance to tumor-associated antigens (TAAs), as these antigens are also expressed in healthy tissues...
  28. pmc Development and validation of the convalescence and recovery evaluation (CARE) for measuring quality of life after surgery
    Brent K Hollenbeck
    Michigan Surgical Collaborative for Outcomes Research and Evaluation, University of Michigan Medical Center, Ann Arbor, MI 48109, USA
    Qual Life Res 17:915-26. 2008
    ..To develop a generic instrument for measuring short-term health status in the recovery period among patients undergoing abdominal and pelvic surgery...
  29. ncbi request reprint Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer
    Arun Sreekumar
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109 0602, USA
    J Natl Cancer Inst 96:834-43. 2004
    ..However, attempts to detect AMACR in circulation have not been successful. Hence, we determined whether an immune response to AMACR could be used as a serum biomarker for prostate cancer...
  30. ncbi request reprint Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy
    Kerstyn M Haram
    Division of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02115, USA
    Prostate 68:1517-30. 2008
    ....
  31. ncbi request reprint The polycomb group protein EZH2 is involved in progression of prostate cancer
    Sooryanarayana Varambally
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109, USA
    Nature 419:624-9. 2002
    ..Thus, dysregulated expression of EZH2 may be involved in the progression of prostate cancer, as well as being a marker that distinguishes indolent prostate cancer from those at risk of lethal progression...
  32. ncbi request reprint Fas-mediated T cell deletion potentiates tumor antigen-specific tolerance in a mouse model of prostate cancer
    Stephanie S Tseng-Rogenski
    Departments of Urology and Pathology, University of Michigan, 1500 E Medical Center Drive, Ann Arbor, MI 48109, USA
    Cancer Immunol Immunother 57:1357-65. 2008
    ..In conclusion, our data show that Fas-mediated TAA-specific CTL apoptosis contributes to T cell tolerance and suggest that such tolerance could be potentiated following TAA-specific immunization...
  33. pmc Prevalence of TMPRSS2-ERG fusion prostate cancer among men undergoing prostate biopsy in the United States
    Juan Miguel Mosquera
    Department of Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Clin Cancer Res 15:4706-11. 2009
    ..We sought to determine the prevalence of TMPRSS2-ERG gene fusion among prostate-specific antigen-screened men undergoing prostate biopsy in the United States...
  34. ncbi request reprint Serum antibodies to huntingtin interacting protein-1: a new blood test for prostate cancer
    Sarah V Bradley
    Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan 48109 0942, USA
    Cancer Res 65:4126-33. 2005
    ..These data suggest that HIP1 plays a functional role in tumorigenesis and that a positive HIP1 autoantibody test may be an important serum marker of prostate cancer...
  35. pmc Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer
    Chandan Kumar-Sinha
    Department of Pathology, University of Michigan Medical School, Ann Arbor, Michigan 48109 0602, USA
    Am J Pathol 164:787-93. 2004
    ..Taken together, our studies suggest that AMACR activity is increased in prostate cancer relative to benign epithelia and suggests that monitoring AMACR activity levels in prostate needle biopsies may have clinical applications...
  36. ncbi request reprint The role of an 80 kDa fragment of E-cadherin in the metastatic progression of prostate cancer
    Rainer Kuefer
    Department of Urology, University of Michigan Medical School, Ann Arbor, Michigan 48109 0944, USA
    Clin Cancer Res 9:6447-52. 2003
    ..The purpose of this study was to evaluate an 80 kDa proteolytic fragment of E-cadherin as a potential biomarker for prostate cancer progression and to identify putative proteases that are responsible for the cleavage of E-cadherin...
  37. ncbi request reprint alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer
    Mark A Rubin
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109 0602, USA
    JAMA 287:1662-70. 2002
    ..Molecular profiling of prostate cancer has led to the identification of candidate biomarkers and regulatory genes. Discoveries from these genome-scale approaches may have applicability in the analysis of diagnostic prostate specimens...
  38. doi request reprint Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection
    Stephen J Eyre
    Division of Urology, Beth Israel Deaconess Medical Center, Boston, Massachusetts 20015, USA
    J Urol 182:2653-8. 2009
    ..We assessed the generalizability of the Prostate Cancer Prevention Trial calculator in a cohort more representative of patients referred for consideration of prostate biopsy in American urology practice...
  39. pmc Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival
    Dinesh S Rao
    Department of Internal Medicine, Division of Hematology and Oncology, University of Michigan Medical School, Ann Arbor, Michigan, USA
    J Clin Invest 110:351-60. 2002
    ..HIP1 represents a putative prognostic factor for prostate cancer and a potential therapy target in prostate as well as colon cancers...
  40. pmc Detection of TMPRSS2-ERG fusion gene expression in prostate cancer specimens by a novel assay using branched DNA
    Bin Lu
    Division of Urology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02115, USA
    Urology 74:1156-61. 2009
    ....
  41. pmc Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice
    Mohamed S Arredouani
    Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, USA
    Prostate 70:1002-11. 2010
    ..We sought to investigate whether androgen deprivation would result in circumventing immune tolerance to prostate TAA by impacting CD8 cell responses...
  42. pmc Defective NKT cell activation by CD1d+ TRAMP prostate tumor cells is corrected by interleukin-12 with α-galactosylceramide
    Michael Nowak
    Division of Hematology Oncology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS ONE 5:e11311. 2010
    ..These data underscore the potential to optimize iNKT-based therapeutic approaches...
  43. ncbi request reprint Identification of the transcription factor single-minded homologue 2 as a potential biomarker and immunotherapy target in prostate cancer
    Mohamed S Arredouani
    Division of Urology, Department of Surgery, Genomics Center, and Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Clin Cancer Res 15:5794-802. 2009
    ..We sought to identify novel PCa tumor-associated antigens (TAA) that are expressed in PCa, absent in nonprostate human tissue, and immunogenic for immune responses restricted by human HLA...
  44. pmc Antigen-specific tumor vaccine efficacy in vivo against prostate cancer with low class I MHC requires competent class II MHC
    Yilin C Neeley
    Department of Urology, University of Michigan, Ann Arbor, Michigan 48109 0330, USA
    Prostate 53:183-91. 2002
    ....
  45. ncbi request reprint Daily prostate targeting using implanted radiopaque markers
    Dale Litzenberg
    Department of Radiation Oncology, University of Michigan Medical Center, Ann Arbor, MI 48103 0010, USA
    Int J Radiat Oncol Biol Phys 52:699-703. 2002
    ..A system has been implemented for daily localization of the prostate through radiographic localization of implanted markers. This report summarizes an initial trial to establish the accuracy of patient setup via this system...
  46. ncbi request reprint Autoantibody signatures in prostate cancer
    Xiaoju Wang
    Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109, USA
    N Engl J Med 353:1224-35. 2005
    ..New biomarkers, such as autoantibody signatures, may improve the early detection of prostate cancer...
  47. ncbi request reprint Racial/ethnic disparities in the treatment of localized/regional prostate cancer
    Willie Underwood
    Department of Urology, University of Michigan, Veterans Affairs Center for Practice Management and Outcomes Research, Ann Arbor, Michigan 48109 0759, USA
    J Urol 171:1504-7. 2004
    ..The effect of race on the use of contemporary definitive therapies, including brachytherapy, and the assessment of Hispanic men with regard to racial/ethnic disparity has not been fully characterized...
  48. ncbi request reprint Living with prostate cancer: patients' and spouses' psychosocial status and quality of life
    Laurel L Northouse
    School of Nursing and the Division of Hematology Oncology, Department of Urology, University of Michigan, Ann Arbor 48109 0482, USA
    J Clin Oncol 25:4171-7. 2007
    ..This study assessed patients' and spouses' quality of life, appraisal of illness, resources, symptoms, and risk for distress across three phases of prostate cancer: newly diagnosed, biochemical recurrence, and advanced...
  49. ncbi request reprint Comprehensive comparison of health-related quality of life after contemporary therapies for localized prostate cancer
    John T Wei
    Veterans Affairs Center for Practice Management and Outcomes Research, Ann Arbor Veterans Affairs Medical Center, USA
    J Clin Oncol 20:557-66. 2002
    ..HRQOL effects of hormonal adjuvants and of cancer control after therapy also lack prior characterization...
  50. ncbi request reprint [The Japanese translation and cultural adaptation of Expanded Prostate Cancer Index Composite (EPIC)]
    Misa Takegami
    Department of Outcome Research, Institute for Health Outcomes and Process Evaluation Research
    Nihon Hinyokika Gakkai Zasshi 96:657-69. 2005
    ....
  51. pmc [-2]proenzyme prostate specific antigen for prostate cancer detection: a national cancer institute early detection research network validation study
    Lori J Sokoll
    Departments of Pathology and Urology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA
    J Urol 180:539-43; discussion 543. 2008
    ..This study evaluated the [-2]proenzyme prostate specific antigen serum marker using a blinded reference specimen set from 3 National Cancer Institute Early Detection Research Network centers from men with an indication for prostate biopsy...

Research Grants16

  1. MODULATING TOLERANCE FOR PROSTATE CANCER ANTIGEN VACCINE
    Martin Sanda; Fiscal Year: 2000
    ..The outcome of these studies will help guide the development of effective immunization strategies targeting hormone-responsive TAA in human prostate and other cancers. ..
  2. Harvard/Michigan Prostate Cancer Biomarker Clinical Ctr
    Martin Sanda; Fiscal Year: 2007
    ..abstract_text> ..
  3. Survivor QOL/Spouse Satisfaction after Prostate Therapy
    Martin Sanda; Fiscal Year: 2006
    ..The findings from this prospective, observational study will provide benchmarks to guide outcomes expectations and to facilitate evidence-based decisions regarding therapy. ..
  4. Survivor QOL/Spouse Satisfaction after Prostate Therapy
    Martin Sanda; Fiscal Year: 2005
    ..The findings from this prospective, observational study will provide benchmarks to guide outcomes expectations and to facilitate evidence-based decisions regarding therapy. ..
  5. Survivor QOL/Spouse Satisfaction after Prostate Therapy
    Martin Sanda; Fiscal Year: 2004
    ..The findings from this prospective, observational study will provide benchmarks to guide outcomes expectations and to facilitate evidence-based decisions regarding therapy. ..
  6. MODULATING TOLERANCE FOR PROSTATE CANCER ANTIGEN VACCINE
    Martin Sanda; Fiscal Year: 2003
    ..The outcome of these studies will help guide the development of effective immunization strategies targeting hormone-responsive TAA in human prostate and other cancers. ..
  7. MODULATING TOLERANCE FOR PROSTATE CANCER ANTIGEN VACCINE
    Martin Sanda; Fiscal Year: 2003
    ..The outcome of these studies will help guide the development of effective immunization strategies targeting hormone-responsive TAA in human prostate and other cancers. ..
  8. Survivor QOL/Spouse Satisfaction after Prostate Therapy
    Martin Sanda; Fiscal Year: 2003
    ..The findings from this prospective, observational study will provide benchmarks to guide outcomes expectations and to facilitate evidence-based decisions regarding therapy. ..
  9. MODULATING TOLERANCE FOR PROSTATE CANCER ANTIGEN VACCINE
    Martin Sanda; Fiscal Year: 2002
    ..The outcome of these studies will help guide the development of effective immunization strategies targeting hormone-responsive TAA in human prostate and other cancers. ..
  10. MODULATING TOLERANCE FOR PROSTATE CANCER ANTIGEN VACCINE
    Martin Sanda; Fiscal Year: 2001
    ..The outcome of these studies will help guide the development of effective immunization strategies targeting hormone-responsive TAA in human prostate and other cancers. ..
  11. MODULATING TOLERANCE FOR PROSTATE CANCER ANTIGEN VACCINE
    Martin Sanda; Fiscal Year: 2001
    ..The outcome of these studies will help guide the development of effective immunization strategies targeting hormone-responsive TAA in human prostate and other cancers. ..
  12. Survivor QOL/Spouse Satisfaction after Prostate Therapy
    Martin Sanda; Fiscal Year: 2002
    ..The findings from this prospective, observational study will provide benchmarks to guide outcomes expectations and to facilitate evidence-based decisions regarding therapy. ..
  13. MODULATING TOLERANCE FOR PROSTATE CANCER ANTIGEN VACCINE
    Martin Sanda; Fiscal Year: 2001
    ..The outcome of these studies will help guide the development of effective immunization strategies targeting hormone-responsive TAA in human prostate and other cancers. ..
  14. MODULATING TOLERANCE FOR PROSTATE CANCER ANTIGEN VACCINE
    Martin Sanda; Fiscal Year: 2000
    ..The outcome of these studies will help guide the development of effective immunization strategies targeting hormone-responsive TAA in human prostate and other cancers. ..
  15. Survivor QOL/Spouse Satisfaction after Prostate Therapy
    Martin Sanda; Fiscal Year: 2007
    ..In so doing, our findings will facilitate appropriately individualizing decision making based on unique characteristics of each prostate cancer patient and his partner. ..